CX11 Shows Weight Loss in Phase 2 Obesity Trial, Corxel Reports

CX11, an investigational oral small-molecule GLP-1 receptor agonist, has displayed continued and consistent weight reduction in patients with obesity or overweight.¹

On June 23, 2026, parent company Corxel Pharmaceuticals reported positive top-line findings from a phase 2 trial of CX11 in adults with obesity or overweight with ≥1 weight-related comorbidity. The company said the trial met its primary endpoints and reported weight loss of up to 11.5% at 36 weeks.¹

“We are delighted with these positive U.S. Phase 2 results, which are consistent with the competitive profile established in the China Phase 3 program,” Bo Liang, MD, PhD, chief medical officer of Corxel, said in a statement. “Together, these datasets reinforce our confidence in CX11 and our conviction to offer patients around the world an effective and highly tolerable option with dosing flexibility.”¹

What the CX11 Phase 2 Trial Reported

The phase 2 trial enrolled 246 US adults with obesity, defined as a body mass index of ≥30 kg/m², or overweight, defined as a body mass index of 27 - <30 kg/m² with ≥1 weight-related comorbidity. Participants were randomized in a 1:1:1:1:1 ratio to receive once-daily CX11 at 120 mg, CX11 at 160 mg, CX11 at 200 mg with slow titration, CX11 at 200 mg with fast titration, or placebo for 36 weeks.¹

At week 36, Corxel reported up to 11.5% weight loss among participants with obesity receiving CX11. The company also reported ongoing weight reduction at a consistent rate, without evidence of a plateau during the 36-week double-blind treatment period.1 However, the announcement did not provide placebo-adjusted weight-loss estimates, confidence intervals, P values, prespecified endpoint definitions, or weight-loss results by each dose and titration cohort. Those details will be important for interpreting the magnitude and consistency of the response across dosing strategies.¹

CX11 Safety and Tolerability Findings

Gastrointestinal adverse events were the most frequently reported safety findings in the phase 2 trial, consistent with the broader incretin-based obesity treatment class. Across CX11 dosing cohorts, Corxel reported nausea rates of 33% to 34%, vomiting rates of 12% to 16%, diarrhea rates of 4% to 12%, and constipation rates of 2% to 12%. The company described these events as generally mild to moderate in severity and reported no severe cases of nausea, vomiting, diarrhea, or constipation.¹

Corxel also reported gastrointestinal adverse events occurred mainly during dose escalation and decreased during the maintenance period. The overall treatment discontinuation rate attributed to gastrointestinal adverse events was 5.0%.¹

The company stated no hepatic safety signal was observed in the US phase 2 study or in a China phase 3 program conducted with partner Vincentage Pharma. Corxel reported that ≥1500 participants have been studied across CX11 clinical studies to date, with no hepatic safety signal identified.¹

Oral GLP-1 Agonist Context and Next Steps

CX11 is being developed as an oral small-molecule GLP-1 receptor agonist for weight management. GLP-1 receptor agonism is an established therapeutic pathway in obesity pharmacotherapy, and injectable incretin-based agents have demonstrated substantial weight loss in large phase 3 trials. Previous trials, like STEP 1, showed that once-weekly semaglutide 2.4 mg is associated with greater mean weight reduction than placebo among adults with overweight or obesity. In SURMOUNT-1, once-weekly tirzepatide was associated with substantial body weight reduction across studied doses in adults with obesity or overweight. These data provide a contemporary efficacy and tolerability benchmark for investigational agents in this class.^2,3

Corxel’s announcement positions CX11 as a candidate for further evaluation in global pivotal studies, but the evidence remains limited to company-reported top-line data for the US phase 2 trial. The China phase 3 findings referenced in the announcement were not detailed in the release, and the US results have not yet been presented with full statistical methods or peer-reviewed data in the source material. Additional reporting from phase 3 studies will be needed to clarify dose selection, durability of weight loss beyond 36 weeks, comparative tolerability, cardiometabolic effects, and longer-term safety.¹

References

1. Corxel Pharmaceuticals. Corxel Pharmaceuticals reports positive top-line results from Phase 2 trial of CX11 in obese and overweight U.S. adults. Published June 23, 2026. Accessed June 23, 2026. https://www.corxelbio.com/en/press-releases/corxel-pharmaceuticals-reports-positive-top-line-results-from-phase-2-trial-of-cx11-in-obese-and-overweight-us-adults

2. Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183

3. Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038